Medical Marijuana, Inc. Subsidiary HempMeds® Mexico President to Speak at 2018 Hemp Industries Association 25th Annual Conference in Los Angeles

SAN DIEGO, Oct. 30, 2018 — Medical Marijuana, Inc.  (OTC:MJNA), the first-ever publicly traded cannabis company in the United States, announced today that subsidiary HempMeds® Mexico President Raul Elizalde will speak at the 2018 Hemp Industries Association 25th Annual Conference (HIACON) on Nov. 2-5 in Los Angeles.

HIACON, held at the LAX Hilton Los Angeles, will bring together over 400 attendees, 55 speakers and many industry thought leaders from around the world. The convention will feature exhibitions, educational tracks and keynote topics such as international hemp policy, regenerative agriculture, quality assurance, international market potential and the 2018 Farm Bill.

At the event, Elizalde will present on the evolving policies in Mexico concerning hemp and cannabidiol (CBD) hemp oil, along with the work that HempMeds® Mexico is doing to increase access to CBD in Mexico. His presentation, “Legal Status of Hemp in Mexico,” will be held in room International B at the LAX Hilton Los Angeles on Sunday, Nov. 4, at 10:30 a.m.

“It is an honor to speak at such a prestigious event and share several exciting updates surrounding hemp in Mexico,” said HempMeds® Mexico President Raul Elizalde. “As Mexico transitions to a federal medical cannabis program, we hope to be a leading voice in hemp and cannabis education and provide policymakers with the necessary information needed to make informed decisions about their citizens’ health.”

Since the establishment of HempMeds® Mexico, the company has worked to promote access to CBD products by supporting non-profit organizations that help provide quick access and by working with the government to establish an importation process that allows patients to get Real Scientific Hemp Oil-X™ (RSHO-X™) with ease. HempMeds® Mexico was also the first company to receive a COFEPRIS federal government import permit for a cannabis product, RSHO-X™, for a medical indication.

“Raul is a well-respected leader in the industry who is frequently invited to speak at events in Latin America and internationally. Last year, he spoke at the World Health Organization (WHO)’s annual Expert Committee on Drug Dependence (ECDD) meeting and explained why CBD should not be a controlled substance and should be classified as a supplement,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “This conference will be another great chance for him to share his expert knowledge and vision for cannabis reform with other notable influencers in the hemp industry.”

About HempMeds® Mexico

HempMeds® Mexico is a Mexico-based company that made history by being the first company to receive a COFEPRIS federal government import permit for the cannabis product RSHO-X™ for a medical indication. HempMeds® Mexico plans to work directly with the Mexican government to safely and legally provide access to CBD hemp oil products. For more information, please review the company’s website at:

About Medical Marijuana, Inc.

We are a company of firsts®. Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.’s portfolio and investment companies, visit

To see Medical Marijuana, Inc.’s corporate video, click here.

Shareholders and consumers are also encouraged to buy CBD oil and other products at Medical Marijuana, Inc.’s shop.


This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.


These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.


Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.


Public Relations Contact:

Andrew Hard

Chief Executive Officer

CMW Media

P. 858-264-6600

[email protected]